Herbert Loong: A tour of landmark immunotherapy trials in sarcomas

Herbert Loong shared a post on X:

”Next up we have sarcoma immunotherapy rockstar Breelyn Wilky taking us on a tour of landmark immunotherapy trials in sarcomas. Checkpoint inhibitors are only the beginning, the answer is in checkpoint plus and cellular-therapies.”

Source: Herbert Loong/X

Herbert H. F. Loong is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO). Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network. Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).

Breelyn Wilky is the Director of Sarcoma Medical Oncology and Associate Professor at the University of Colorado, where she also serves as Director of Translational Sarcoma Research and Deputy Associate Director of Clinical Research at the University of Colorado Cancer Center. She specializes in both benign and malignant bone and soft tissue disorders, including sarcomas. Alongside patient care, she is a clinical and translational researcher focused on developing innovative therapies beyond traditional chemotherapy.